Interpublic outpaces industry, again, in Q3 earnings
CEO Michael Roth praised IPG’s performance in healthcare in Q3 as helping to lead U.S. growth.
-
-
Publicis Groupe said to be divesting part of its US health business
The holding company reported organic growth of 1.3% in the third quarter, but said the Publicis Health Services business dragged down its growth. -
To recruit for clinical trials, throw out the usual ad playbook: study
New research on what attracts patients to volunteer for clinical trials was presented at Digital Pharma East in Philadelphia. The windup: be transparent.
LATEST NEWS
Five things for pharma marketers to know: Friday, October 19, 2018
FDA considers banning vape sales in convenience stores; AbbVie settles Humira biosimilar patent dispute; 71% of voters say healthcare is most important midterm issue.
Read the October 2018 Digital Edition
The October 2018 digital edition includes MM&M’s annual Career and Salary Survey, pipeline watch, and the pro ad report for the first half of 2018.
Five things for pharma marketers to know: Thursday, October 18, 2018
Takeda-Shire merger receives Japanese approval; Publicis Groupe said to be divesting Publicis Health Services; Anthem and HealthCore launch type 2 diabetes study
Why pharma should start paying more attention to Instagram
Facebook Health’s Danielle Salowski and Merck’s Nancy Nolan shared best practices for Instagram at Digital Pharma East in Philadelphia.
Trump orders drug companies to disclose list prices in DTC ads. Will it actually happen?
PhRMA pushed back on the HHS plan for disclosing drug prices in ads, putting itself in Trump’s Twitter crosshairs, but experts say flaws in the plan could impede its rollout anyway.
Five things for pharma marketers to know: Wednesday, October 17, 2018
Merck hires Nike exec as chief information, digital officer; Minnesota sues three insulin makers over pricing; UnitedHealth Q3 beats expectations.
GSK moves global Panadol ad business from Grey to bespoke WPP team
WPP will create integrated campaigns and content encompassing advertising, digital, shopper activation and PR.
Why healthcare agencies must redefine their role in philanthropic work
Agencies that view philanthropy merely as pro-bono work shortchange their people and are missing a chance to bring private-sector creativity to public health needs.
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
The war on cancer took a big turn with the birth of checkpoint inhibitors. Laura Entis explores their scientific and commercial impact, the unanswered questions, and what’s next for this enormously successful group of immunotherapies.
A timeline of key moments in the development of checkpoint inhibitors
Immunotherapy’s modern era has been characterized by a tremendous amount of scientific and regulatory activity. Trace the road to the Nobel.
